This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Katz, M. S. Articles by Leibel, S. A. Search for Related Content PubMed PubMed Citation Articles by Katz, M. S. Articles by Leibel, S. A. Social Bookmarking                            What's this?

Predictors of Biochemical Outcome With Salvage Conformal Radiotherapy After Radical Prostatectomy for Prostate Cancer

From the Departments of Radiation Oncology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY.

Address reprint requests to Michael J. Zelefsky, MD, Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021; email: zelefskm{at}mskcc.org.

Purpose: To identify predictors of biochemical outcome following radiotherapy in patients with a rising prostate-specific antigen (PSA) after radical prostatectomy for prostate cancer.

Patients and Methods: One hundred fifteen patients with a rising PSA after radical prostatectomy received salvage three-dimensional conformal radiotherapy (3D-CRT) alone or with neoadjuvant androgen deprivation. Tumor-related and treatment-related factors were evaluated to identify predictors of subsequent PSA failure.

Results: The median follow-up time after 3D-CRT was 42 months. The 4-year actuarial PSA relapse-free survival, distant metastasis-free survival, and overall survival rates were 46%, 83%, and 95%, respectively. Multivariate analysis, which was limited to 70 patients receiving radiation without androgen deprivation therapy, showed that negative/close margins (P = .03), absence of extracapsular extension (P < .01), and presence of seminal vesicle invasion (P < .01) were independent predictors of PSA relapse after radiotherapy. Neoadjuvant androgen deprivation did not improve the 4-year PSA relapse-free survival in patients with positive margins, extracapsular extension, and no seminal vesicle invasion (P = .24). However, neoadjuvant androgen deprivation did improve PSA relapse-free survival when one or more of these variables were absent (P = .03).

Conclusions: Salvage 3D-CRT can provide biochemical control in selected patients with a rising PSA after radical prostatectomy. Among patients with positive margins and no poor prognostic features, 77% achieved PSA control after salvage 3D-CRT. Salvage neoadjuvant androgen deprivation therapy may improve short-term biochemical control, but it requires further study.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				H. Ide, J. Nakashima, H. Kono, E. Kikuchi, H. Nagata, A. Miyajima, K. Nakagawa, and M. Oya Prognostic Stratification in Patients Who Received Hormonal Therapy for Prostate-specific Antigen Recurrence after Radical Prostatectomy Jpn. J. Clin. Oncol., October 16, 2009; (2009) hyp133v1. [Abstract] [Full Text] [PDF]

				B. J. Trock, M. Han, S. J. Freedland, E. B. Humphreys, T. L. DeWeese, A. W. Partin, and P. C. Walsh Prostate Cancer-Specific Survival Following Salvage Radiotherapy vs Observation in Men With Biochemical Recurrence After Radical Prostatectomy JAMA, June 18, 2008; 299(23): 2760 - 2769. [Abstract] [Full Text] [PDF]

				A. J. Stephenson, P. T. Scardino, M. W. Kattan, T. M. Pisansky, K. M. Slawin, E. A. Klein, M. S. Anscher, J. M. Michalski, H. M. Sandler, D. W. Lin, et al. Predicting the Outcome of Salvage Radiation Therapy for Recurrent Prostate Cancer After Radical Prostatectomy J. Clin. Oncol., May 20, 2007; 25(15): 2035 - 2041. [Abstract] [Full Text] [PDF]

				A. K. Lee and A. V. D'Amico Utility of Prostate-Specific Antigen Kinetics in Addition to Clinical Factors in the Selection of Patients for Salvage Local Therapy J. Clin. Oncol., November 10, 2005; 23(32): 8192 - 8197. [Abstract] [Full Text] [PDF]

				S. B. Hayes and A. Pollack Parameters for Treatment Decisions for Salvage Radiation Therapy J. Clin. Oncol., November 10, 2005; 23(32): 8204 - 8211. [Abstract] [Full Text] [PDF]

				S. Naito Evaluation and Management of Prostate-specific Antigen Recurrence After Radical Prostatectomy for Localized Prostate Cancer Jpn. J. Clin. Oncol., July 1, 2005; 35(7): 365 - 374. [Abstract] [Full Text] [PDF]

				K. Numata, K. Azuma, K. Hashine, and Y. Sumiyoshi Predictor of Response to Salvage Radiotherapy in Patients with PSA Recurrence after Radical Prostatectomy: the Usefulness of PSA Doubling Time Jpn. J. Clin. Oncol., May 1, 2005; 35(5): 256 - 259. [Abstract] [Full Text] [PDF]

				A. J. Stephenson, S. F. Shariat, M. J. Zelefsky, M. W. Kattan, E. B. Butler, B. S. Teh, E. A. Klein, P. A. Kupelian, C. G. Roehrborn, D. A. Pistenmaa, et al. Salvage Radiotherapy for Recurrent Prostate Cancer After Radical Prostatectomy JAMA, March 17, 2004; 291(11): 1325 - 1332. [Abstract] [Full Text] [PDF]

				H. I. Scher, M. Eisenberger, A. V. D'Amico, S. Halabi, E. J. Small, M. Morris, M. W. Kattan, M. Roach, P. Kantoff, K. J. Pienta, et al. Eligibility and Outcomes Reporting Guidelines for Clinical Trials for Patients in the State of a Rising Prostate-Specific Antigen: Recommendations From the Prostate-Specific Antigen Working Group J. Clin. Oncol., February 1, 2004; 22(3): 537 - 556. [Abstract] [Full Text] [PDF]